Prophase Labs Inc
NASDAQ:PRPH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Prophase Labs Inc
Cash & Cash Equivalents
Prophase Labs Inc
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Prophase Labs Inc
NASDAQ:PRPH
|
Cash & Cash Equivalents
$678k
|
CAGR 3-Years
-57%
|
CAGR 5-Years
10%
|
CAGR 10-Years
-14%
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash & Cash Equivalents
$9.3B
|
CAGR 3-Years
5%
|
CAGR 5-Years
16%
|
CAGR 10-Years
-4%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash & Cash Equivalents
$10.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
16%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Cash & Cash Equivalents
$1.1B
|
CAGR 3-Years
40%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-11%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Cash & Cash Equivalents
$14.6B
|
CAGR 3-Years
5%
|
CAGR 5-Years
13%
|
CAGR 10-Years
6%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash & Cash Equivalents
$7.3B
|
CAGR 3-Years
52%
|
CAGR 5-Years
15%
|
CAGR 10-Years
7%
|
|
Prophase Labs Inc
Glance View
ProPhase Labs, Inc. is a medical science and technology company. The company is headquartered in New York City, New York and currently employs 129 full-time employees. The firm operates through two segments: diagnostic services and consumer products. The diagnostic services segment provides COVID-19 diagnostic information services to a range of customers in the United States, including health plans, third-party payers and government organizations. The consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of over-the-counter (OTC) consumer healthcare products and dietary supplements in the United States and also provide personal genomics products and services. The firm is also engaged in the development and marketing of dietary supplements under the TK Supplements brand. The Company’s TK Supplements product line includes Legendz XL, a male sexual enhancement and Triple Edge XL, an energy and stamina booster.
See Also
What is Prophase Labs Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
678k
USD
Based on the financial report for Dec 31, 2024, Prophase Labs Inc's Cash & Cash Equivalents amounts to 678k USD.
What is Prophase Labs Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
-14%
Over the last year, the Cash & Cash Equivalents growth was -58%. The average annual Cash & Cash Equivalents growth rates for Prophase Labs Inc have been -57% over the past three years , 10% over the past five years , and -14% over the past ten years .
